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Epigallocatechin-3-gallate (EGCG) is a candidate therapeutic for Down syndrome (DS) phenotypes 
based on in vitro inhibition of DYRK1A, a triplicated gene product of Trisomy 21 (Ts21). Consumption of 
green tea extracts containing eGcG improved some cognitive and behavioral outcomes in DS mouse 
models and in humans with Ts21. In contrast, treatment with pure EGCG in DS mouse models did not 
improve neurobehavioral phenotypes. This study tested the hypothesis that 200 mg/kg/day of pure 
EGCG, given via oral gavage, would improve neurobehavioral and skeletal phenotypes in the Ts65Dn DS 
mouse model. Serum EGCG levels post-gavage were significantly higher in trisomic mice than in euploid 
mice. Daily EGCG gavage treatments over three weeks resulted in growth deficits in both euploid 
and trisomic mice. Compared to vehicle treatment, EGCG did not significantly improve behavioral 
performance of Ts65Dn mice in the multivariate concentric square field, balance beam, or Morris water 
maze tasks, but reduced swimming speed. Furthermore, EGCG resulted in reduced cortical bone 
structure and strength in Ts65Dn mice. These outcomes failed to support the therapeutic potential of 
EGCG, and the deleterious effects on growth and skeletal phenotypes underscore the need for caution 
in high-dose eGcG supplements as an intervention in DS.
Epigallocatechin-3-gallate (EGCG), the main polyphenol found in green tea, has been hypothesized to reduce 
the risk or pathogenesis of several neurodegenerative and cardiovascular diseases, as well as cancer1–4. The effects 
of EGCG or EGCG-containing green tea extracts have been assessed in over 100 clinical trials in a wide-range of 
diseases and disorders that represent diverse underlying etiologies (search as of December 2019 on Clinicaltrials.
gov), consistent with multiple cellular and molecular mechanisms that are thought to be modified by EGCG5–7.
EGCG was initially identified as a candidate therapeutic treatment for Down syndrome (DS) phenotypes 
based largely on the in vitro demonstration that EGCG inhibits Dual-specificity tyrosine-phosphorylation reg-
ulated kinase 1A (DYRK1A) activity8,9. DYRK1A is a serine-threonine kinase located on human chromosome 
21 (Hsa21) and found in three copies in individuals with Trisomy 21 (Ts21) and in most DS mouse models10–12. 
DYRK1A is a dosage-sensitive gene that is particularly active during embryonic and perinatal development13,14. 
Differential expression of Dyrk1a in genetically modified mice (both overexpression and underexpression) has 
been correlated with deleterious phenotypes including cognitive deficits, neurodevelopmental abnormalities, low 
body weight, and reduced brain size15,16. The hypothesis that trisomic DYRK1A is a major contributor to DS phe-
notypes17,18 and the demonstration that EGCG inhibits DYRK1A activity in vitro has fueled enthusiasm for the 
hypothesis that EGCG and green tea extracts could be an effective nutraceutical therapy for DS19.
Preclinical evaluation of effects of consuming EGCG-containing green tea extracts on DS phenotypes have 
been assessed in DS mouse models, including Ts65Dn mice that are trisomic for approximately half of the genes 
found in three copies in Ts21 and mice that are transgenic for Dyrk1a (Table 1). Mice have typically been given 
green tea extracts in drinking water or chow and various improvements have been shown in anatomical, cellular 
and behavioral traits. Reports of beneficial effects of EGCG-containing green tea extracts in mouse models led to 
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two clinical trials of the therapeutic potential of green tea extracts in individuals with DS. A three-month treat-
ment of green tea extract (45% EGCG, 9 mg/kg/day EGCG) improved performance on a subset of measures on 
a battery of cognitive tests, including visual recognition memory20. A subsequent randomized, placebo-control, 
double-blind study administered the same supplement (or placebo) to individuals with DS in combination with 
cognitive training for 12 months with follow-up testing 6 months after treatment ended. The group receiving 
EGCG displayed significantly higher scores in two of the 15 measures of the battery of cognitive tests (visual 
recognition immediate memory; inhibitory control) and in one of the nine measures of adaptive behavior21. The 
modest gains in a limited set of measures of cognitive and adaptive function in these clinical trials suggest some 
benefit of the green tea supplement containing EGCG.
In contrast to the studies in Table 1, experiments in our laboratory that administered pure EGCG to Ts65Dn 
mice found no significant improvement in DS cognitive or behavioral phenotypes. In those studies, EGCG was 
administered in the drinking water beginning in early adolescence in dosages of ~9, 20, or 50 mg/kg/day22,23. The 
multiple, substantial differences in the methods and types of EGCG administration in different experimental 
mouse models make it difficult to reconcile outcome differences by direct comparison across studies. One impor-
tant factor that cannot be ruled out is that polyphenol mixtures of green tea extracts contain other catechins 
with bioactive potential [epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epicatechin (EC)] that are 
not present in pure EGCG treatments, and high plasma levels of these other catechins have been reported after 
consumption of green tea extract24,25. Another key factor is that the daily dosage of EGCG also varied across the 
mouse model studies. In studies using green tea extract (in drinking water or chow), daily EGCG consumption 
has ranged from ~20 to 200 mg/kg/day. In the pure EGCG studies, the daily dosage was either ~9, 20, or 50 mg/
kg/day, raising the possibility that the lack of effects of pure EGCG in DS mouse models may be due to lower daily 
dosages. In most studies, the daily amount and temporal distribution of EGCG/green tea extract was controlled 
by the consumption pattern of the mouse rather than by the experimenter. Levels of EGCG in blood or tissue 
produced by the treatments have rarely been reported, further hindering comparisons of EGCG effects across 
studies. The bioavailability of ECGC or other bioactive green tea polyphenols is quite low in rodents (4.9 to 6.7%) 
after oral administration and varies with route of administration and species26–29. These considerations highlight 
the need to determine levels of EGCG that are produced in preclinical DS models of EGCG treatment.
To begin to address these gaps, the current study delivered EGCG in dosages of 200 mg/kg/day via oral gavage. 
This dose was chosen to achieve a high daily exposure within the range of EGCG doses reported to be given to 
individuals with DS by their caregivers30 and that approximated the highest daily dosage reported for the preclin-
ical studies (non-DS) with green tea extract (in drinking water). Gavage EGCG treatment with 217 mg/kg/day 
for two weeks did not produce tissue histopathology in mice27. The current study first determined serum levels of 
EGCG after acute treatment. Then, cognitive and skeletal DS phenotypes were assessed during a 3-week gavage 
treatment. Four main hypotheses were tested: (1) that acute doses of 200 mg/kg EGCG will produce measurable 
blood levels of EGCG in trisomic mice; (2) that daily oral gavage treatments will improve cognitive and skeletal 
phenotypes in the trisomic mice; (3) that the DS mice will have elevated expression of DYRK1A protein in brain; 
and (4) that DYRK1A-associated kinase activity in brain and bone will be reduced by EGCG.
Mouse model Sex Age EGCG
Treatment 
duration Observed Effects Ref




(27% EGCG, 1.2 mg/day EGCG)
Gestation-
adulthood
• Normaled brain size
• Improved novel object recognition memory
58
TgDyrk1A female 1 month
Mega Green Tea Extract (45% 
EGCG, 2–3 mg/day EGCG, 
~40–60 mg/kg/day EGCG23)
1 month
• Reduced DYRK1A kinase activity in the 
hippocampus
• Reduction to WT levels of the density of 
proliferating (Ki67+) dentate gyrus neural progenitor 
cells
• Normalized proportion of proliferating cells exiting 
the cell cycle
59
mBACtgDyrk1a male 4–6 months
LifeExtension
For Longer Life
(45% EGCG, 120–200 mg/kg/day 
EGCG)
4–6 weeks
• Restored spine density
• Improved long term potentiation
• Normalized associated biochemical markers
54
TgDyrk1a and 
Ts65Dn male 3 months
Mega Green Tea Extract (45% 







(27% EGCG, 60 mg/kg/day EGCG)
Mega Green Tea Extract (45% 
EGCG, 60 mg/kg/day EGCG)
4–6 weeks
• Improved novel object recognition discrimination 
in YACtgDyrk1a mice
• Improved spontaneous alternation in Ts65Dn mice
60
TgBACDyrk1A male 2 months FontUp (0.5% EGCG, 5 mg/kg/day EGCG) 2–8 days
• Increased plasma homocysteine
• Increased glutathione
• Decreased alanine aminotransferase
• Increased BDNF
• Normalization of erk and Akt phosphorylation
31
Table 1. Preclinical treatment of Down syndrome mouse models with EGCG-containing green tea extracts 
and/or other formulations.
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Results
Serum concentrations of eGcG following acute gavage treatment. The concentrations of EGCG 
(µg/ml) in the serum after acute dosage of 200 mg/kg EGCG treatment for euploid and trisomic mice at 30, 60, 
and 90 minutes post-gavage are shown in Table 2. The majority of serum samples were collected at 60 minutes; the 
others were randomly sampled at either 30 or 90 minutes. Non-zero levels of EGCG were detected in all mice. As 
shown in Fig. 1, at 60 minutes the distributions for euploid and trisomic groups differed significantly (U = 155.5, 
p = 0.022, n = 29), with trisomic mice having higher ECCG concentrations (Mdn = 0.134 µg/ml [0.292 µM]; mean 
rank =18.96) than euploid mice (Mdn = 0.018 µg/ml [0.039 µM]; mean rank=11.78). Serum concentration mean 
ranks across the three time points did not differ significantly for either genotype (Kruskal-Wallis test, p’s>0.20).
Body weight with chronic treatment. As expected, Ts65Dn mice weighed significantly less than euploid 
mice at the beginning of treatment (18.9 + 0.8 g and 21.6 + 0.7 g, respectively; see Fig. 2) and the group difference 
was evident throughout the 3-week treatment period [main effect of genotype, F(1,38) = 7.322, p = 0.010]. Daily 
EGCG gavage resulted in significant growth restriction over weeks compared to PBS gavage in both the euploid 
and the Ts65Dn groups, with differences between PBS and EGCG groups increasing over time [treatment × day 
interaction, F(3.19,121.22) = 9.874, p < 0.001; main effect of treatment, F(1,38) = 4.126, p = 0.049; main effect of 
day, F(21,798) = 18.475, p < 0.001]. Despite the trend for larger effects of EGCG on the weights of Ts65Dn mice 
as treatment progressed, no treatment × genotype interactions were statistically significant.
Multivariate concentric square field (MCSF). There were no significant group differences in locomotor 
activity (total number of zone entries) or in the category of exploratory behavior on either Day 1 or Day 2, indi-
cating that neither genotype nor EGCG treatment significantly affected overall activity or exploration of novel 
features of the MCSF. In addition, there were no main or interactive effects of EGCG treatment on any of the five 
behavioral categories. Trisomic mice differed from euploid littermates on the other three categories of behavior 
(shelter seeking, risk assessment, risk taking), shown in Fig. 3.
On the first day of MCSF testing (left panels), the trisomic mice as compared to euploid mice engaged in sig-
nificantly more shelter seeking [main effect of genotype, F(1,32)=7.126, p = 0.012], significantly less risk taking 
behavior [main effect of genotype, F(1,33)=10.786, p = 0.002], and significantly more risk assessment [main 
effect of genotype, F(1,33)=6.043, p = 0.019]. Similarly on Day 2, trisomic mice again displayed significantly 
more shelter seeking [main effect of genotype, F(1,33)=4.415, p = 0.043] and significantly less risk taking [main 
























Table 2. Median (and interquartile range) of serum EGCG concentrations (µg/ml) at 30, 60, and 90 minutes 
after gavage treatment with 200 mg/kg EGCG. aSignificantly different from Euploid 60-minute group (p = 0.022, 
Mann-Whitney U).
Figure 1. Serum concentration of Epigallocatechin-3-gallate (EGCG) 60 minutes after gavage treatment 
with 200 mg/kg EGCG in male Ts65Dn mice and euploid littermates. EGCG levels were determined by liquid 
chromatography and tandem mass spectroscopy (LC-MS/MS) using standards ranging between 0.001 and 0. 
06 µg/mL. All samples yielded a non-zero value, and the Ts65Dn mice had significantly higher EGCG levels 
than the euploid mice (p = 0.022, Mann-Whitney U).
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outcomes suggest that the trisomic mice are more risk averse and engage more in shelter seeking than euploid 
mice in the complex novel environment of the MCSF, and EGCG treatment did not affect these phenotypes.
Balance beam. The mean (±SEM) number of paw slips at each of the three beam widths are shown in 
Table 3. All mice exhibited an increase in paw slips as the widths decreased (main effect of beam width, F(1,80) 
= 86.92, p ≤ 0.001), but there were no group differences at any beam width as (no main or interactive effects of 
genotype or treatment).
Morris Water Maze (MWM). Acquisition. The trisomic mice showed the expected deficits in acquisition 
of place learning. Mean daily latencies to find the platform (Fig. 4, panel A) declined significantly across the seven 
days of training [main effect of day, F(6,222) = 14.18, p < 0.001], but the euploid mice showed significantly greater 
reductions in mean daily latencies than did the trisomic mice [genotype × day interaction, F(6,222) = 3.746, 
p = 0.001; main effect of genotype, F(1,37) = 20.217, p < 0.001]. EGCG treatment did not significantly affect 
escape latencies. Path lengths (Table 4) also significantly declined over days for all groups [main effect of day, 
F(6,222) = 27.935, p < 0.001], and the trisomic mice had significantly longer mean path lengths [main effect 
of genotype F(1,37) = 16.648, p < 0.001]. There were no significant main or interactive effects of EGCG treat-
ment on path length. EGCG treatment significantly increased floating behavior (Fig. 4, middle panel) in both 
the trisomic and euploid mice [main effect of EGCG: F(1,37) = 17.597, p < 0.001]. In addition, trisomic mice as 
compared to euploid littermates spent significantly more time floating, main effect of genotype [F(1,37) = 8.893, 
p = 0.005]. The trend for increasing time floating over days in the EGCG-treated trisomic mice did not yield sta-
tistically significant interactive effects of day. However, the increased floating over days in EGCG-treated groups 
was associated with significant reductions in swimming speed in the EGCG-treated groups of both genotypes 
(Table 4) that emerged across days [treatment × day interaction, F(6,222) = 2.878, p = 0.01; main effect of treat-
ment, F(1,37) = 9.016, p = 0.005; main effect of day, F(6,222) = 11.057, p < 0.001]. The acquisition deficits of the 
trisomic mice were also associated with significantly more thigmotaxic behavior (time spent within 25 cm of the 
wall) compared to euploid mice (Fig. 4, Panel C). Thigmotaxis generally declined over the course of acquisition 
(main effect of day; F(6,222) = 13.288, p < 0/001), but the trisomic mice showed significantly less reduction in 
thigmotaxis over days than euploid mice [day × genotype interaction, F(6,222) = 3.506, p = 0.007; main effect of 
genotype, F(1,37) = 16.248, p < 0.001].
Probe trial. A repeated measures ANOVA on percent time in in the four quadrant zones on the probe trial 
yielded the expected overall main effect of quadrant, F(3,111) = 22.949, p < 0.001, with the generally greater 
percent time in the Target counter consistent with the expression of spatial memory (Fig. 5). The euploid mice 
given PBS spent significantly more time in the Target zone than any of the other three groups [genotype × quad-
rant interaction, F(3,111) = 3.235, p = 0.025; main effect of genotype, F(1,37) = 9.060, p = 0.005; protected LSD 
post hoc tests on time in Target, p < 0.05], consistent with stronger spatial search strategies for the euploid-PBS 
group. Unexpectedly, treatment with EGCG significantly disrupted the expression of place biases in the probe 
trial [treatment × quadrant interaction, F(3,111) = 3.940, p = 0.01] and the EGCG-treated euploid group spent 
significantly less time in the Target counter than the euploid-PBS group. Notably, the trisomic mice given EGCG 
failed to express a significant place bias the probe trial. The probe trial deficits in search biases in the trisomic 
groups were associated with alterations in other performance measures (see Table 5). These included reduced 
probe trial path length in trisomic mice [main effect of genotype, F(1,37) = 10.009, p = 0.003], slower swimming 
speed [main effect of genotype, F(1,37) = 9.732, p = 0.004], increased thigmotaxis time [main effect of genotype, 
F(1,37) = 11.495, p = 0.002], and increased time floating [main effect of genotype, F(1,37) = 9.525, p = 0.004]. In 
addition, the adverse effects of EGCG treatment on probe performance were evident in EGCG-induced increased 
Figure 2. Body weights of male Ts65Dn and euploid littermates over the 3-week course of gavage treatment. 
Littermates were randomly assigned to either PBS or EGCG daily gavage treatments beginning on PD 42. 
EGCG treatment resulted in significant growth restriction in both genotypes that emerged over the 3-week 
treatment period.
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thigmotaxis time [main effect of treatment, F(1,37) = 4.969, p = 0.032] and increased time floating [main effect 
of treatment, F(1,37) = 4.634, p = 0.038].
Micro ct analysis of femora. Trabecular bone architecture measures in the distal femoral metaphysis were 
all impacted by trisomy (Table 6). Ts65Dn mice as compared to euploid mice exhibited significantly reduced 
bone mineral density, bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), and trabecular num-
ber (Tb.N). Trabecular separation (Tb.Sp) was significantly greater in trisomic as compared to euploid mice. 
Treatment with 200 mg/kg/day EGCG had no significant impact on the trabecular bone.
Figure 3. Multivariate Concentric Square Field (MCSF). Significant differences were seen between trisomic 
and euploid mice for shelter seeking, risk taking and risk assessment. No effect of EGCG treatment was seen in 
Ts65Dn or littermate control mice.
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Beam Width (mm)a
Group Treatment n 12 9 6
Euploid PBS 13 2.4 ± 0.3 4.6 ± 0.5 6.4 ± 0.7
Euploid ECGG 11 2.0 ± 0.5 4.7 ± 0.7 5.1 ± 1.2
Ts65Dn PBS 12 3.1 ± 0.6 4.7 ± 0.7 6.3 ± 0.6
Ts65Dn EGCG 8 2.1 ± 0.4 4.8 ± 0.6 7.2 ± 1.0
Table 3. Balance Beam Performance. Mean (± SEM) number of paw slips at each beam width. aMain effect of 
beam width (p < 0.001).
Figure 4. Morris water maze acquisition. [Top panel]: Mean (± SEM) latencies (on four trials per session) to 
reach the hidden platform over the seven days of acquisition training. Acquisition deficits in the trisomic mice 
were confirmed by the significantly longer escape latencies as compared to euploid littermates, and EGCG 
treatment failed to improve those deficits. [Middle panel]: Mean (± SEM) time spent floating (on the four trials 
per session) over the seven days of acquisition training. EGCG treatment produced significant increases in 
floating behavior over the training period, and the Ts65Dn mice floated more than euploid littermates. [Bottom 
panel]: Mean (± SEM) time spent within 25 cm of the tank wall (thigmotaxis) over acquisition training. Euploid 
mice showed significantly greater reduction in thigmotaxis over days than trisomic mice.
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Femurs from trisomic mice were smaller than euploid littermates, and treatment caused the femur to have 
a larger marrow cavity with a similar overall size leading to decreased cortical thickness and area. Trisomic as 
compared to euploid mice had reduced total cross-sectional area (CSA), marrow area (Ma.Ar), cortical area (Ct.
Ar), periosteal bone surface (Ps.BS), endocortical bone surface (Es.BS), maximum moment of inertia (Imax) and 
minimum moment of inertia (Imin). Treatment with 200 mg/kg/day EGCG significantly decreased cortical thick-
ness (Ct.Th) and Ct.Ar and increased Ma.Ar and endocortical bone surface (Es.BS) (Table 6).
In agreement with prevailing knowledge, trisomy negatively impacted the mechanical properties in the femur. 
The femurs of trisomic mice were significantly weaker than euploid mice, indicated by reduced ultimate force, 
stiffness, increased displacement to yield, yield stress, modulus, and resilience. These effects are likely attributed to 
the size of the femur rather than material properties. Treatment with 200 mg/kg EGCG decreased ultimate force 
and stiffness. There was a significant genotype × treatment interaction for ultimate stress. Despite having smaller 
bones (as reflected in decreased whole bone stiffness and strength), trisomic bones appeared to have better mate-
rial properties (stiffer and stronger bone material). Treatment, if anything, made the bones less stiff and strong, 
potentially through its effects on bone size rather than material changes (Table 7).
Measure Group
MWM Acquisition Training Day




(n = 12) 8.95 (0.53) 6.33 (0.72) 3.89 (0.37) 4.20 (0.59) 2.70 (0.52) 3.43 (0.48) 2.84 (0.75)
Eu + EGCG
(n = 11) 9.12 (0.99) 5.40 (0.79) 3.50 (0.60) 3.55 (0.59) 3.13 (0.48) 3.36 (0.64) 3.34 (0.57)
Ts + PBS
(n = 9) 9.69 (1.14) 8.17 (0.82) 7.13 (1.02) 7.16 (0.95) 5.75 (0.77) 4.26 (1.03) 5.69 (1.34)
Ts + EGCG




(n = 12) 0.190 (0.008) 0.202 (0.010) 0.200 (0.008) 0.204 (0.006) 0.143 (0.015) 0.179 (0.004) 0.183 (0.012)
Eu + EGCG
(n = 11) 0.185 (0.010) 0.158 (0.012) 0.143 (0.016) 0.145 (0.017) 0.140 (0.015) 0.146 (0.017) 0.143 (0.014)
Ts + PBS
(n = 9) 0.189 (0.010) 0.189 (0.010) 0.168 (0.008) 0.156 (0.014) 0.149 (0.013) 0.140 (0.015) 0.156 (0.012)
Ts + EGCG
(n = 9) 0.175 (0.016) 0.160 (0.016) 0.128 (0.014) 0.121 (0.014) 0.121 (0.018) 0.143 (0.020) 0.121 (0.019)
Table 4. Additional performance measures during acquisition training in the Morris water maze. Eu=euploid; 
Ts=trisomic; PBS/EGCG = chronic gavage treatment. aMain effect of day. bMain effect of gentoype. cMain effect 
of treatment. dMain effect of day. eInteractive effect of treatment × day.
Figure 5. Morris water maze probe trial search. For each of the four groups, the percent of time (of 
the 60-second probe trial) that was spent in each of the four virtual counters are shown as function of 
quadrant relative to the location of the target quadrant (Target, Adjacent-clockwise, Opposite, Adjacent-
counterclockwise). Note the significant reduction in target search bias in the trisomic mice, and the reduction 
in target search bias in the groups given EGCG. *Significantly greater than other three quadrants for the same 
group; #Significantly greater than the time in Target of all other groups.
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DYRK1A protein levels. As shown in Fig. 6, for the cerebral cortex (top panel) the trisomic mice had sig-
nificantly higher relative DYRK1A levels than euploid mice [main effect of genotype, F(1,19)=5.230, p = 0.034], 
with a 2.1-fold average increase relative to euploid mice (collapsed across treatment). There were no significant 
differences in DYRK1A protein levels between genotypes in the hippocampus and cerebellum, and EGCG treat-
ment did not significantly affect DYRK1A protein levels in any region.
Kinase activity. As shown in Fig. 7, kinase activity was significantly higher in the cerebellum than in the 
cortex or hippocampus [main effect of region, F(2,55.8)=36.88, p < 0.001], and differences between trisomic and 
euploid mice depended on region [region × genotype interaction, F(1.59,55.81)= 7.899, p < 0.001; main effect of 
genotype, F(1,35)=9.696, p = 0.004]. Moreover, the effects of EGCG treatment depended on brain region [region 
× treatment interaction, F(1.59,55.81)= 5.002, p < 0.001]. In the cerebral cortex, follow-up two-way ANOVA 
confirmed significant effects of genotype [F(1,40)=28.59, p < 0.001] and EGCG treatment [F(1,40)=7.01, 
p = 0.012]. Post hoc LSD tests indicated that the PBS-treated trisomic mice had higher kinase activity than 
PBS-treated and EGCG-treated euploid groups (p < 0.001 and p = 0.019, respectively), and ECGC significantly 
reduced kinase activity in the trisomic mice compared PBS-treated trisomic mice (p = 0.005). In contrast, kinase 
activity in the cerebellum and hippocampus did not differ significantly between trisomic and euploid groups. 
EGCG treatment produced a significant and unexpected increase in kinase activity both in the cerebellum [main 
effect of treatment, F(1,37)=8.314, p = 0.007] and the hippocampus [main effect of treatment, F(1,38)=5.332, 
p = 0.026]. Post hoc LSD tests indicated that the ECGG-induced increase in kinase activity in the cerebellum was 
significant only in the euploid group (p = 0.001), but in the hippocampus group differences within each genotype 
did not reach significance.
For the femur, there were no statistically significant effects of genotype or treatment on kinase activity 
(Euploid + PBS:117.8 ± 13.3, n = 13; Euploid+EGCG: 97.0 ± 19.5, n = 13; Trisomic+PBS: 95.0 ± 13.5, n = 7; 


















































Table 5. MWM Probe trial additional performance measures. Data for each group are shown as mean ± (SEM). 












   Bone mineral density (BMD) (g/mm3)a 284 ± 12 248 ± 15 222 ± 11 208 ± 19
   Percent bone volume (BV/TV) (%)a 31.4 ± 1.8 26.6 ± 2.0 22.1 ± 1.4 20.8 ± 2.4
   Trabecular thickness (Tb.Th) (mm)a 0.079 ± 0.003 0.076 ± 0.003 0.071 ± 0.002 0.069 ± 0.002
   Trabecular separation (Tb.S) (mm)a 0.165 ± 0.006 0.182 ± 0.011 0.201 ± 0.008 0.205 ± 0.009
   Trabecular number (Tb.N) (1/mm)a 3.96 ± 0.17 3.50 ± 0.21 3.12 ± 0.21 3.00 ± 0.36
Cortical bone
   Total cross sectional area (CSA) (mm2)a 1.77 ± 0.05 1.84 ± 0.07 1.58 ± 0.04 1.50 ± 0.07
   Marrow area (Ma.Ar) (mm2)a,b 0.76 ± 0.03 0.88 ± 0.03 0.62 ± 0.03 0.68 ± 0.02
   Cortical area (Ct.A) (mm2)a,b 1.01 ± 0.03 0.96 ± 0.05 0.95 ± 0.02 0.81 ± 0.06
   Cortical thickness (Ct.Th) (mm)b 0.26 ± 0.01 0.24 ± 0.01 0.26 ± 0.01 0.22 ± 0.01
   Periosteal bone surface (P.Bs) (mm)a 5.56 ± 0.07 5.66 ± 0.10 5.34 ± 0.06 5.20 ± 0.13
   Endocortical bone surface (Es.BS) (mm)a,b 3.84 ± 0.08 4.11 ± 0.06 3.56 ± 0.07 3.65 ± 0.06
   Imax (mm4)a 0.30 ± 0.02 0.31 ± 0.03 0.27 ± 0.01 0.23 ± 0.03
   Imin (mm4)a 0.14 ± 0.01 0.15 ± 0.01 0.11 ± 0.00 0.09 ± 0.01
   Polar moment of inertia (J) (mm4) 0.44 ± 0.02 0.45 ± 0.04 0.37 ± 0.02 0.32 ± 0.04
Table 6. Skeletal structure in trabecular and cortical bone of femora from Ts65Dn and euploid mice given 
200 mg/kg/day EGCG or PBS (Mean ± SEM). aMain effect of genotype. bMain effect of treatment.
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Discussion
The first step in understanding the discrepant outcomes across studies using treatments of EGCG or green tea 
extracts containing EGCG in DS mouse models is to identify the in vivo levels of EGCG produced by different 
treatments. This study documents serum levels of EGCG in a mouse model of DS following controlled daily 
dosing of 200 mg/kg pure EGCG using oral gavage, confirming our hypothesis that this dose and route of EGCG 
treatment produced measurable levels of EGCG in the blood in Ts65Dn and euploid mice. Other experiments 
with considerably less EGCG in combination with other components have also shown measurable EGCG levels 
in the brain and bone of TgDyrk1A mice31. This experimenter-controlled gavage dosing contrasts with most other 
studies administering EGCG in DS mouse models that typically provide EGCG (or green tea extracts containing 
EGCG and other catechins) in the drinking water, in which the daily dosage and pattern of EGCG (or green tea 
extract) consumed over the day is controlled by the drinking behavior of the subject rather than directly by the 
experimenter. In normosomic Swiss albino mice, a single oral gavage EGCG dose of 108 mg/kg produced peak 
EGCG levels of ~0.13 µg/ml27. By comparison, the daily gavage administration of 200 mg/kg in the two-day proto-
col of the current study produced median EGCG levels of 0.018 µg/ml in the serum of euploid mice one hour after 
the gavage on the second day, approximately 14% of the levels reported for the Swiss albino mice. Notably, the 
median serum EGCG level in trisomic mice in this study was 0.098 µg/ml, significantly higher than the euploid 
levels but closer to the peak level at 60 minutes when 108 mg/kg EGCG was given to Swiss albino mice27. The 
differences in blood levels of EGCG between the two studies may have arisen from any of multiple procedural 
differences. Ramachandran et al. used female Swiss albino mice, administered a single dose of EGCG using 4% 
DMSO and PBS as a vehicle, and performed multiple blood draws (without specifying whether serum or plasma 
was used), whereas the current study used male Ts65Dn mice on an ~50% B6 50% C3H background, adminis-
tered EGCG in PBS without the use of DMSO once a day for two days, and obtained blood samples only once 
per animal via terminal cardiac puncture to measure serum EGCG. DMSO was likely used in the Ramachandran 
study to achieve the higher concentrations of treatment; the current study avoided DMSO because of its inhibi-
tory effects on enzymatic activity32–34. The Ramachandran et al. study also used the divalent cation chelator EDTA 
as an anticoagulant for plasma/serum collection; EDTA can interfere with enzymatic activities that metabolize 
EGCG that may alter the temporal profile of EGCG elimination35. Conversely, our method of deproteinating the 
serum samples using acetonitrile may have precipitated proteins bound to EGCG, resulting in a reduced serum 
concentration. We utilized LC-MS/MS that measures the quantities of specific ionized fragments of EGCG, 
because it is more specific and sensitive than the HPLC method that was used by Ramachandran et al.36. The 
higher serum EGCG concentrations of the trisomic compared to euploid mice after gavage treatment in this study 
may reflect differences in pharmacokinetic processes related to absorption, distribution, metabolism or elimina-
tion of EGCG, analyses that are beyond the scope of the current study. The short (two-day) duration of the acute 
gavage dosing provided only a snapshot of EGCG serum concentration and may not accurately model changes 
due to effects of sustained daily gavage treatment from PD 42 to PD 68 used in the chronic dosing in this study.
Variation in the in vivo effects of EGCG (or green tea extract) across different studies may result from multiple 
chemical or pharmacokinetic properties of EGCG, including chemical degradation of EGCG over time in solu-
tion, the low bioavailability of EGCG, or the potential for biotransformation in the digestive tract prior to absorp-
tion37,38. ECCG bioavailability using acute oral gavage of pure EGCG in Swiss albino mice was reported to be only 
about 6.7%, and gavage doses of 108 mg/kg yielded peak plasma levels (Cmax) of 0.14 µg/ml and an elimination 
half-life (t½) of 68.4 minutes27. Bioavailability may also change over time with consumption. The peak plasma 
ECGC levels resulting from a bolus intragastric challenge dose of 750 mg/kg EGCG in fasting naïve CF-1 mice 
was 1.3-fold higher than in a comparison group of mice that had consumed EGCG in the diet over the previous 2 
weeks (Cmax of 15.45 µg/ml as compared to 6.65 µg/ml, respectively). In normosomic A/J mice consuming either 
0.1% or 0.6% green tea extract in the drinking water, plasma levels of ECGC also declined over the first week, sta-
bilizing around 0.80 µg/ml and 200–250 µg/ml, respectively39. Given the potential for wide variation in the blood 
levels of EGCG that depend on route, formulation, and type of supplement treatment provided, identifying the 
blood levels of EGCG and other catechins produced by treatment with EGCG or green tea extracts in DS mouse 
models is an essential first step in determining the basis for differences in outcomes on DS phenotypes.
Although no formal histological measures of toxicity were determined in the mice of this study, the chronic 
daily gavage treatment with 200 mg/kg significantly encumbered growth in euploid and trisomic mice. This dos-
age was chosen because of the lack of improvement in behavioral phenotypes in trisomic mice after treatment 
in our previous studies with lower daily doses of pure EGCG (~9 to ~50 mg/kg/day) in the drinking water22,23 
and reported high doses of EGCG consumed by individuals with DS30. The reduced body weights in the current 
study were similar to other studies where a high dosage of EGCG was given by oral gavage27,40. Nevertheless, the 
200 mg/kg/day EGCG treatment in the present study did not cause attrition due to death or other major adverse 
effects; a previous study reported only mild toxicity when an oral EGCG dosage of about half of the present study 
was used27. EGCG administration via oral gavage has much lower bioavailability than intravenous or intraperi-
toneal treatments, and intraperitoneal treatments with 108 mg/kg/day EGCG caused mortality within 8 days27. 
When green tea extract including 48.4% EGCG was given by oral gavage to B6C3F1 mice (similar background 
as the mice in the current study) for 5 days a week for 14 weeks, hepatotoxicity and olfactory and respiratory 
epithelial necrosis were seen in mice given 250 and 500 mg/kg green tea extract (~121 and 242 mg/kg EGCG)40. 
A meta-analysis of animal studies determined an acceptable daily intake of only 4.6 mg/kg/day EGCG using a 
strict safety standard41. An analysis of body composition in individuals with DS who were given green tea extract 
with ~9 mg/kg/day EGCG for 12 months showed a trend in males for less body weight gain and lower BMI 
at 12 months and 6 months after treatment was completed21,42. In general, it is evident that chronic treatment 
with EGCG or green tea extract is not without risk, and differences in EGCG serum concentrations between 
euploid and trisomic mice after a similar EGCG treatment in this study warrant quantification of EGCG levels 
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Figure 6. Western blot analyses of relative DYRK1A protein levels for cerebral cortex, hippocampus, and 
cerebellum in 68-day-old euploid and trisomic male mice. DYRK1A from each brain region was normalized to 
actin as a loading control, then each sample ratio was expressed as a relative proportion of the mean value of the 
euploid-PBS control group for that brain region. DYRK1A was significantly overexpressed in trisomic mice only 










Yield Force (N) 14.4 ± 1.1 11.8 ± 1.4 13.6 ± 0.6 11.7 ± 1.8
Ultimate Force (N)a,b 23.1 ± 1.0 20.6 ± 1.5 19.8 ± 0.6 17.0 ± 1.4
Displacement to Yield (µm)a 119.3 ± 7.7 107.9 ± 7.0 138.3 ± 11.3 142.3 ± 15.6
Postyield Displacement (µm) 533.0 ± 97.2 416.50 ± 96.2 384.8 ± 58.9 563.00 ± 170.5
Total Displacment (µm) 652.3 ± 97.5 524.4 ± 94.4 523.1 ± 67.0 705.3 ± 169.5
Stiffness (N/mm)a,b 137.4 ± 7.6 120.5 ± 8.2 112.5 ± 6.1 90.2 ± 8.0
Work to Yield (mJ) 0.97 ± 0.11 0.75 ± 0.14 1.08 ± 0.13 1.02 ± 0.26
Postyield Work (mJ) 9.8 ± 1.5 6.3 ± 1.3 6.8 ± 1.0 6.8 ± 0.9
Total Work (mJ) 10.8 ± 1.5 7.0 ± 1.3 7.9 ± 1.1 7.8 ± 1.0
Yield Stress (MPa)a 117.0 ± 8.1 93.3 ± 8.3 132.7 ± 8.2 128.6 ± 11.7
Ultimate Stress (MPa)c 187.8 ± 7.4 163.4 ± 5.4 191.9 ± 7.7 194.9 ± 4.8
Strain to Yield (me) 17.2 ± 1.1 15.9 ± 1.1 17.7 ± 1.4 17.9 ± 2.2
Total Strain (me) 94.0 ± 14.4 76.9 ± 14.0 67.0 ± 8.5 85.8 ± 18.8
Modulus (GPa)a 7.78 ± 0.45 6.58 ± 0.28 8.49 ± 0.44 8.38 ± 0.47
Resilience (MPa)a 1.13 ± 0.12 0.87 ± 0.14 1.36 ± 0.19 1.39 ± 0.30
Toughness (MPa) 12.7 ± 1.8 8.3 ± 1.4 10.1 ± 1.6 11.8 ± 2.1
Table 7. Mechanical data of femora from Ts65Dn and euploid mice given 200 mg/kg/day EGCG or PBS 
(Mean ± SEM). aMain effect of genotype. bMain effect of treatment. cGenotype × treatment interaction. 
Abbreviations: N: Newtons; mJ: millijoules; MPa: megapascal; me: microstrain; GPa: gigapascal.
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in individuals with and without Ts21. Treatments of EGCG in humans should monitor possible weight loss and 
toxicity, especially with long duration of treatment27,41,43,44.
Even with the relatively high dose of EGCG administered in this study to trisomic mice that produced phar-
macologically relevant levels of EGCG in the blood, there were only limited behavioral and no skeletal improve-
ments in Ts65Dn mice, mostly disconfirming our second hypothesis that this EGCG treatment would improve 
behavioral and skeletal deficits in DS mouse models. Similar to other studies, the current investigation confirmed 
that trisomic and euploid mice have significant behavioral differences22,23. The behavior in the MCSF showed that 
trisomic mice exhibited more shelter seeking and less risk taking on both days of testing, and EGCG treatment 
had no effect on these phenotypes. In contrast, our previous study using a lower concentration of EGCG in the 
drinking water did not find a significant effect of genotype on risk taking, but did find a significant genotype × 
treatment interaction in which EGCG decreased risk taking in trisomic mice but increased it in euploid mice23. 
The lower risk taking in trisomic mice in the current study compared to the lack of differences in trisomic and 
euploid control mice (drinking control fluid) in our previous study suggests that the daily stress of gavage may 
have differentially influenced the risk-taking behavior of trisomic and control mice, as measures of risk-taking 
and risk assessment have been related to stress and anxiety in other studies using the MCSF test45–47. For the 
risk assessment measure, trisomic mice showed increases as compared to euploid mice on the first evaluation 
day, similar to our previous study with the lower concentration with EGCG in the drinking water. In contrast, 
the increased shelter seeking of the trisomic mice in the current study was not found in the previous study with 
EGCG in the drinking water23, again suggesting a differential effect of gavage treatment.
As has been shown in our previous studies, trisomic mice were deficient in both the acquisition and probe trial 
phases of the MWM22,23. Trisomic mice had significantly less reduction in escape latencies over training and spent 
significantly less time in the target quadrant zone during the probe trial compared to euploid groups. These defi-
cits in trisomic mice were associated with significantly increased amount of time near the wall (thigmotaxis) and 
increased time spent floating, as has been previously reported48. EGCG treatment did not improve these deficits 
in trisomic mice. In fact, the gavage EGCG treatment significantly increased float time and concurrently reduced 
swimming speed during acquisition in both trisomic and euploid mice. In the probe trial, trisomic mice showed 
decreased swimming speed along with increased time floating and increased thigmotaxis, and EGCG treatment 
interfered with the expression of place biases, reducing the time in the target zone and increasing thigmotaxis in 
both genotypes.
Our previous study administering 50 mg/kg/day EGCG in the drinking water23 found comparable deficits in 
water maze acquisition and probe trial performance in trisomic mice that were not improved by EGCG, but in 
that study the EGCG treatment did not interfere with the probe trial performance. The disruption of acquisition 
and probe trial performance with the gavage dosing of EGCG in the current study, including the overall increase 
in floating behavior and thigmotaxis, suggests that this high dose had adverse effects on performance of the water 
maze task. Time floating in the MWM is often not reported in behavioral studies of DS mouse models, and given 
the results of the present study, should be quantified to account for performance differences that may confound 
the typically-reported measures of learning, i.e., latency and path length measures for acquisition and target zone 
search biases for spatial memory. The present study did not include a cued (visible-platform) version of the water 
maze task, leaving open the question as to whether the increase in floating by EGCG-treated trisomic mice as 
training progressed is specific to the spatial task48. Overall, the enhanced deficits on the behavioral tests of mice 
given EGCG treatment over training may be due to interactive effects of increased stress of the gavage, though it 
appears that most of the adverse behavioral effects may be attributed to the high dose of EGCG.
In a previous study, administration of 9 mg/kg/day of pure EGCG in the drinking water significantly improved 
trabecular bone deficits observed in Ts65Dn mice49, but neither 50 mg/kg/day of EGCG23 nor 200 mg/kg/day of 
EGCG (current study) improved these trabecular bone deficits in Ts65Dn mice. To the contrary, these higher dos-
ages of EGCG were detrimental to several bone parameters including cortical area and cortical thickness in both 
euploid and trisomic mice22,23. Low doses (<10 mg/kg/day) of EGCG-containing green tea supplements also were 
detrimental to cortical bone, although they did improve some trabecular parameters37. Treatments with 200 mg/
kg EGCG decreased ultimate force, and to some extent, yield force. EGCG reduced stiffness in both trisomic and 
Figure 7. DYRK1A-related kinase activity in brain regions of Ts65Dn and control mice with and without 
EGCG treatment. The area under the curve (AUC) of the the p-FAM-Woodtide fluorescence was measured 
from protein isolated from brain regions of treated and untreated mice. DYRK1A-related kinase activity was 
significantly higher in the cerebellum than the other brain areas. A reduction in kinase activity in trisomic as 
compared to euploid mice was only found in the cerebral cortex. ECGC treatment increased kinase activity in 
the hippocampus and cerebellum, with kinase activity in Ts65Dn + EGCG treatment significantly higher than 
Ts65Dn + PBS treated animals.
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euploid mice, indicating that a high dosage of EGCG negatively affected the mechanical and material properties 
of all bones. A 12-month treatment of green tea extract containing ~9 mg/kg/day EGCG in humans with DS 
noted lowered bone mass, especially in females21,42. These and previous data noting adverse effects in bone prop-
erties after treatment with EGCG or green tea extracts containing EGCG23,37 indicate that monitoring of bone 
parameters during and after treatment is warranted.
The last two hypotheses tested in this study were whether DYRK1A protein levels were elevated in different 
regions of the brain in the adult stage, and whether 200 mg/kg EGCG treatment reduced kinase activity (of which 
DYRK1A was expected to contribute) in brain and bone at ~10 weeks of age. Significant DYRK1A overexpres-
sion in the brain of Ts65Dn mice as compared to euploid mice was evident only in the cerebral cortex, with no 
differences in the cerebellum or hippocampus. In a previous study of brain regions in ~10-week-old Ts65Dn and 
euploid mice23, EGCG treatment reduced the kinase activity in the cerebral cortex in trisomic, but not euploid 
mice. Conversely, EGCG treatment increased kinase activity in the cerebellum and hippocampus of the mice, 
with a specific increase in the cerebellum of euploid mice. These data suggest that DYRK1A is not elevated in 
the cerebellum or hippocampus at ~10 weeks of age in trisomic mice, and that EGCG does not affect DYRK1A 
activity in the brain.
Although EGCG has been shown to inhibit DYRK1A activity in vitro (using the Woodtide peptide)8,50, there 
is little evidence to directly support that EGCG inhibits DYRK1A activity in vivo, and perhaps more importantly, 
that EGCG is specific in limiting only DYRK1A activity. The varied results in the different brain regions and bone 
after EGCG treatment may reflect a more broad inhibitory mechanism of EGCG than just decreasing DYRK1A 
activity6,7,51. The results from these and other studies suggest that three copies of Dyrk1a lead to overexpression of 
DYRK1A protein in some but not all tissues and may be dependent on developmental time52, as DYRK1A levels 
in forebrain from Ts65Dn mice decreased from postnatal day 5 through day 3553. Increased DYRK1A levels and 
activity in this and other studies indicates that, although EGCG may not lower DYRK1A activity in vivo, trisomic 
DYRK1A may still be a viable target for skeletal and cognitive phenotypes associated with DS18,51,52.
conclusions
Studies describing behavioral improvements after administrations of green tea extracts report EGCG doses rang-
ing from ~40 to ~200 mg/kg/day12,20,54. However, it is difficult to ascertain the independent contribution of pure 
EGCG in these reported behavioral improvements, given the multiple catechins with bioactive potential that are 
present in the green tea extract. With doses of ~9 to ~200 mg/kg/day of pure EGCG, Ts65Dn mice have largely 
failed to significantly improve behavioral and cognitive deficits22,23. It may be that the other components besides 
(or in combination with) EGCG included in the green tea extracts are having positive effects on learning and 
memory in Ts65Dn mice. Additionally, other effects of green tea polyphenols including EGCG besides altering 
DYRK1A activity may account for some of the beneficial effects see when green tea polyphenols are given to DS 
model mice7. Taken together, the results from four separate studies from our laboratory strongly suggest that pure 
EGCG does not improve cognitive and behavioral deficits related to Ts21 in DS mouse models. Pure EGCG has 
not proven to be an effective therapeutic treatment for improving DS-related cognitive deficits in Ts65Dn mice, 
and it may carry some dose-related risk for interfering with growth and skeletal integrity.
Methods
Animals. Ts(1716)65Dn (Ts65Dn—stock number 001924 from the Jackson Laboratories [Bar Harbor, ME]) 
females (~50% C57BL/6 J and ~50% C3H/HeJ background) were bred to B6C3F1 males (stock number 100010) 
and produced Ts65Dn and euploid progeny. New Ts65Dn females and B6C3F1 males were purchased from the 
Jackson Laboratories approximately every six months and introduced into the breeding colony. Only male mice 
were used for subsequent testing; Ts65Dn females were reserved for colony maintenance. Offspring were gen-
otyped using the Ts65Dn breakpoint PCR55 and screened for the C3H-derived retinal degeneration mutation 
Pde6brd1 that causes blindness within the first few weeks of life56 (Protocol 22421: Standard PCR Assay - Generic 
Pde6b, The Jackson Laboratory). Mice homozygous for Pde6brd1 were excluded from the study. After weaning, 
male mice were group-housed in a reverse 12:12 light:dark cycle with white light off between 0700-1900 to 
accommodate behavioral testing during the dark phase of the circadian cycle. Experiments with animals were 
carried out in accordance with the NIH Guide for the Care and Use of Laboratory Animals and received prior 
IACUC approval from IUPUI (protocols SC213R and SC255R).
Epigallocatechin-3-gallate (EGCG) treatment and serum levels. EGCG treatment was prepared 
fresh daily by dissolving EGCG (>95% purity, as determined by LC/MS analyses37) in phosphate buffered saline 
(PBS) at a concentration of 15 mg/mL. The prepared EGCG was administered via oral gavage (13.34 mL/kg body 
weight) once daily (200 mg/kg/day). Daily oral gavage of an equivalent volume of PBS (13.34 mL/kg body weight) 
was given as the vehicle control.
Acute treatment for serum level determination. For the determination of serum levels of EGCC, 6-week-old 
male Ts65Dn and euploid mice were treated with 200 mg/kg/day EGCG (based on the weight of each animal) 
once a day for two days and euthanized under isoflurane anesthesia followed by cervical dislocation at 30, 60, or 
90 minutes after the second treatment. Blood was collected by a cardiac draw, centrifuged to isolate the serum, 
and the serum was snap frozen.
Analysis of serum EGCG levels. Serum was analyzed by liquid chromatography tandem mass spectroscopy 
(LC-MS/MS) to quantify the concentrations of EGCG37. EGCG concentration was analyzed using an Agilent 
1200SL HPLC coupled with an Agilent 6520 quadrupole time-of-flight mass spectrometer (MS). Samples were 
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separated using reverse phase chromatography with a Zorbax Eclipse Plus C18 column (2.1 × 50 mm, 1.8 µm 
particle size) operating at a temperature of 55 °C with a solvent ratio of 30% A (water with 0.1% formic acid) and 
70% B (acetonitrile with 0.1% formic acid). Standards were made with serum from PBS-treated mice at 0, 0.001, 
0.003, 0.005, 0.01 and 0.06 μg/mL. The area under the curve (AUC) from the abundance of fragments 124.7 m/z 
and 168.8 m/z were used for quantification.
Chronic treatment for DS phenotype assessment. For the long-term assessment of behavioral, biochemical, and 
structural outcomes, male Ts65Dn and euploid mice were treated once daily by gavage with either 200 mg/kg 
EGCG or PBS (based on the weight of each animal) beginning on postnatal day (PD) 42 for the duration of the 
study (PD 68). Behavioral testing began on PD 49 with gavage treatments administered 30 minutes before behav-
ioral testing.
timeline for behavioral testing. The cognitive and behavioral tasks were administered as previously 
described22,23. Starting on PD 49, mice underwent two days of testing on the multivariate concentric square field 
maze (MCSF), followed by three consecutive days of balance beam testing (PD 51–53). After two rest days, the 
mice were trained on the Morris water maze (MWM) task from PD 56–63. On PD 68, the mice were euthanized 
under isoflurane followed by cervical dislocation. The cerebral cortex, cerebellum, and hippocampus were rapidly 
dissected upon sacrifice, snap frozen, and stored at −80 °C for subsequent protein extraction. The mouse car-
casses were stored at 4 °C before femurs were extracted. After extraction, femurs were wrapped with gauze soaked 
in 1X PBS then frozen at −20 °C before microcomputed tomography (μCT) scanning and mechanical testing.
Multivariate concentric square field maze (MCSF). Mice were tested in the MCSF on PD 45 and 
46. The MCSF apparatus is a complex multi-compartment novel environment with various distinct areas and 
structures that animals may explore, including compartments that are open, elevated, or sheltered and that have 
characteristic features such as a hurdle, a ramp, an aperture for nose poking, and a small dark enclosure23. For 
each session, the animal was placed in the center zone facing the wall with no openings; its activity was video 
recorded for each 20-minute session in dim light (15–20 lx) in all areas except for the dark corner room (1–2 lx) 
and the lighted bridge area (320 lx). The MCSF was thoroughly cleaned between testing sessions with 70% eth-
anol. Photocell counts of nose pokes and fecal boli were recorded after each 20-minute session by the experi-
menter. All sessions were scored by three independent observers blind to experimental treatment and genotype. 
Results were averaged to obtain the score value that was used for each animal. The correlation of scores across all 
measures between the three raters was r ≈ + 0.99. Behavioral measures were obtained using The Observer XT 
Version 8 software (Noldus Information Technology, Wageningen, The Netherlands), and included measures of 
frequency of entries, duration, duration per visit, and latency to initial visit for each defined location within the 
MCSF. Measurements of rearing were not available due to unreliable identification of defined rearing events in 
video playback.
Balance beam (BB). The balance beam task was administered as previously described23. Briefly, the balance 
beam task was conducted in red light over a 3-day period in which the first 2 days were allotted for training and 
the third day designated for testing. On the first of two training days, mice were trained to walk across a raised 
19 mm wide wooden beam, starting at varying distances from the box. On the second day, mice were trained to 
cross the 12 mm beam three consecutive times without stopping. On the third day, mice were tested on three trials 
each of the 12-mm, 9-mm, and 6-mm beams. Trials were recorded using a Logitech camera positioned on the end 
of the beam opposite the goal box to capture hind-leg slips, defined as either hind-leg slipping off the top surface 
of the beam. The number of hind-leg slips during each recorded trial was scored by three independent scorers 
blind to the genotype and treatment.
Morris water maze (MWM). The MWM task was administered as previously described using a 125-cm 
diameter tank filled with 26 °C water made opaque with white tempera paint23. Briefly, this task was carried out 
over an eight-day period in which the first seven days consisted of acquisition trials in which an invisible plat-
form (nine cm diameter) was submerged in the center of the same quadrant of the tank (designated as the target 
location). The eighth day was a probe day in which the platform was removed to quantify the spatial search 
behavior. On acquisition days, cohorts of 2–4 mice were tested in daily sessions, with each mouse given four 
trials (60 seconds maximum) to find the submerged escape platform, after which the mouse remained on the 
platform for 10 seconds. The mouse either found the platform within the 60 seconds or was moved to the plat-
form by the experimenter after 60 seconds elapsed. Four different start locations (out of eight possible locations) 
were pseudo-randomly assigned for each trial within a given session (one start location per quadrant). All start 
locations were randomized over the 7-day acquisition period. Twenty-four hours after the last training day, mice 
were given a single probe trial, in which the platform was removed and each mouse was placed in a start location 
directly opposite of the quadrant that had contained the platform and was allowed to swim for 60 seconds. All days 
of testing were recorded with video tracking using HVS image software (HVS Image, Mountain View, CA, USA).
Microcomputed tomography (μct) imaging and analysis. Left femurs were extracted and stored in 
PBS-soaked gauze at −20 °C and thawed prior to scanning with a high-resolution μCT system (SkyScan 1172, 
Bruker microCT, Belgium). Scanning conditions were calibrated each day using two cylindrical hydroxyapa-
tite phantoms (0.25 and 0.75 g/cm3 CaHA). The distal condyle to the 3rd trochanter of each femur was scanned 
using 60 kV, 12 µm resolution, and Al 0.5 mm filter. Femurs were rewrapped with PBS-soaked gauze and stored 
at −20 °C for future mechanical testing. Femur scans were reconstructed, rotated, and analyzed using NRecon 
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(SkyScan, Bruker microCT, Belgium), DataViewer, CTan (SkyScan, Bruker microCT, Belgium), and MatLab soft-
ware (MathWorks, Inc. Natick, MA). Trabecular and cortical bone analyses were performed using a previously 
published protocol37,57. Bone mineral density (BMD) was calculated using the hydroxyapatite phantoms as a 
standard. Analysis for the cortical bone was performed on a standard site chosen as 7 transverse slices at 60% of 
the bone’s total length away from the proximal end of the distal growth plate. Trabecular bone analysis was per-
formed on the region of the distal metaphysis defined as 10% of total bone length, starting at the proximal end of 
the distal growth plate. The region of interest within the metaphyseal region was auto-segmented to exclude outer 
cortical bone using a custom Matlab code37,57.
Mechanical testing. The mechanical properties of the femora were determined by 3-point bending 
(ElectroForce 3200; Eden Prairie, MN USA). The left femora were thawed to room temperature and tested in the 
AP direction (anterior surface in tension). The loading span was set at 6 mm and a preload of 0.5 N applied to 
the midpoint of the bone to establish contact. Once preloaded, the bone was monotonically tested to failure at a 
displacement rate of 0.025 mm/sec.
High performance liquid chromatography (HPLC) kinase activity assay. Isolated protein was 
quantified by Bradford assay and subjected to a HPLC-based kinase activity assay as previously described23. 
Briefly, ~100 µg protein was incubated at 37 °C with a 5-carboxyfluorescein tagged Woodtide peptide (2 mg/mL) 
and kinase buffer. The addition of ATP (1 mM) started the reaction and samples were incubated at 37 °C for 
30 min. The reaction was stopped by the addition of HClO4 (15%) and centrifuged at 4 °C for 10 min at 14,655 g. 
The supernatant was analyzed on the Agilent 1260 HPLC. Separation was performed using initial conditions of 
85% H2O with 0.1% formic acid (solvent A) and 15% acetonitrile with 0.1% formic acid (solvent B) held for 1 min, 
followed by a stepwise gradient ending with 5% solvent A and 95% solvent B over 11 min. FAM-Woodtide fluo-
rescence was measured using a fluorescence detector with an excitation wavelength of 485 nm and an emission of 
530 nm. The peak height and retention time determined the area under the curve for the p-FAM-Woodtide and 
FAM-Woodtide. Results were analyzed using OpenLab CDS Chemstation software.
Western Blot quantification of DYRK1A protein. Isolated protein lysates (20 μg) from the cerebral cor-
tex, hippocampus, and cerebellum were resolved by electrophoresis on polyacrylamide gels (Bolt 4–12% Bis Tris 
Plus Gels), then transferred to PVDF membranes. Membranes were blocked in 5% milk in Tris Buffered Saline 
with 0.1% Tween 20 (TBS-T), incubated overnight at 4 °C in primary antibodies diluted in 5% milk-TBS-T as 
follows: rabbit anti-DYRK1A antibody, 1:500 (A303–802A, Bethyl Laboratories); mouse anti-beta-actin, 1:5000 
(A2228, Sigma Aldrich), and labeled with donkey anti-rabbit IgG AlexaFluor 790 and donkey anti-mouse IgG 
AlexaFluor 680 secondary antibodies (1:10,000, Jackson Immunoresearch). Fluorescence was detected using a 
LI-COR CLx Imager. Each membrane included protein samples from each of the three brain regions from four 
different mice, one from each genotype and treatment combination. DYRK1A for each sample was normalized 
to actin and each normalized ratio was expressed as a proportion relative to the mean of the euploid-PBS group 
for the particular brain region.
Data analyses. EGCG levels and body weight. The data for EGCG serum levels at 30, 60, and 90 minutes 
following acute gavage were not normally distributed (Shapiro-Wilk’s test, p < 0.001) so they were analyzed with 
non-parametric rank-order statistics. Samples from 51 mice were included in the serum EGCG analysis (see 
Table 2 for group numbers); values of one trisomic mouse and one euploid mouse were far beyond the assay 
distribution (> 10 standard deviations above the mean) and were excluded from the analysis. Group differences 
between euploid and trisomic mice at each time point were analyzed using Mann-Whitney U tests; comparison of 
effects at different times within each genotype used a one-way Kruskal-Wallis test. Body weights over the chronic 
treatment period were analyzed with a repeated-measures ANOVA using the Greenhouse-Geisser correction for 
violations of the assumption of sphericity.
Multivariate Concentric Square Field. The mean of each of the individual measures (e.g., latency to initial visit, 
duration, frequency, and duration per visit) was generated from the three independent observer scores, and scores 
for each of the five behavioral categories were tabulated as shown in Table 1 of our previous study23. Data from 
13 subjects were unavailable for the analysis due to technical problems with the video recording of a session that 
precluded reliable scoring. The subjects that were unavailable were distributed as follows: one trisomic mouse 
given PBS, three trisomic mice given EGCG, five euploid mice given PBS, and four euploid mice given EGCG); 
one other animal was lethargic on the test day so was not tested (trisomic mouse given EGCG).
For the remaining mice, the total entries data (summed across the seven MCSF zones) constituted an under-
lying continuous variable and was distributed normally (Shapiro-Wilk’s W test), so those sums were analyzed 
separately for each day with a two-way factorial ANOVA with genotype and treatment as grouping factors. The 
other four behavioral categories (risk-taking, risk assessment, shelter seeking and exploratory behavior) involved 
measures that used different scales (time or frequency). As described in our previous study [20], the data for each 
contributing measure were first rank ordered for a given day, then the ranks for each measure contributing to a 
category were summed across the measures for each animal for that day to provide a single summed score for the 
animal for each category. The summed scores of subject ranks for each of these four categories formed a contin-
uous underlying variable for each category and were normally distributed within each group in all but two cases 
(Shapiro-Wilk’s W test). The summed rank data for each category for a given day were analyzed (separately for 
each day) with a two-way factorial ANOVA with genotype and treatment as grouping factors.
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Balance beam. The number of paw slips on the balance beam was analyzed using a mixed ANOVA with treat-
ment group and genotype as between-group factors, and beam width (12 mm, 9 mm and 6 mm) as a repeated 
measure.
Morris water maze. The average daily latency, path length, time (sec) spent within 25 cm of the tank wall (thig-
motaxis time), time spent floating, and swimming speed over the seven days of training were analyzed using a 
mixed ANOVA with day as a repeated measure and genotype and treatment as between-group factors. For the 
probe trial, the time spent in a virtual disc (27 cm diameter) centered in the target quadrant (target) and the 
average time spent in equivalent virtual discs centered in each of the other three quadrants (non-target) were 
analyzed using a mixed ANOVA with treatment group and genotype as between-group factors and quadrant 
(four quadrants identified as target, adjacent-clockwise, opposite, adjacent counterclockwise) as a within-subjects 
measure. Additional measures in the probe trial (path length, thigmotaxis time, floating time, and speed) were 
analyzed with factorial ANOVAs with genotype and treatment as between-subjects factors. As acquisition train-
ing progressed, five of the 46 mice began to adopt a floating posture upon being placed in the pool that persisted 
for large portions of most trials (>30 sec) of all subsequent training sessions (two trisomic mice given PBS, one 
trisomic given EGCG, and two euploid mice, one given PBS and one given EGCG). These five were excluded 
from the MWM analyses. On the probe trial, one trisomic mouse (given EGCG) that had completed acquisition 
training in typical fashion, subsequently adopted the floating posture for 42 seconds of the 60-second probe trial 
and was excluded from the probe analysis.
Brain and bone measures. The normalized DYRK1A values (as a proportion of the euploid-PBS control 
mean) were analyzed by two-way ANOVAs (separate for each brain region) with genotype and treatment as 
between-subjects factors. For skeletal measurements, the measures that were not normally distributed were trans-
formed to achieve normality. The bone parameters (Tables 6 and 7) were analyzed with two-way ANOVAs using 
genotype and treatment as between-subjects factors.
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